Columbia Laboratories (NASDAQ: JNP) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.
Volatility and Risk
Columbia Laboratories has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500.
Valuation and Earnings
This table compares Columbia Laboratories and Theravance Biopharma’s top-line revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Columbia Laboratories has higher revenue and earnings than Theravance Biopharma. Columbia Laboratories is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings for Columbia Laboratories and Theravance Biopharma, as reported by MarketBeat.com.
||Strong Buy Ratings
Columbia Laboratories presently has a consensus price target of $29.00, suggesting a potential upside of 178.85%. Theravance Biopharma has a consensus price target of $43.33, suggesting a potential upside of 86.54%. Given Columbia Laboratories’ higher possible upside, research analysts clearly believe Columbia Laboratories is more favorable than Theravance Biopharma.
This table compares Columbia Laboratories and Theravance Biopharma’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Insider and Institutional Ownership
39.2% of Columbia Laboratories shares are owned by institutional investors. Comparatively, 86.6% of Theravance Biopharma shares are owned by institutional investors. 11.6% of Columbia Laboratories shares are owned by company insiders. Comparatively, 6.1% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Columbia Laboratories beats Theravance Biopharma on 8 of the 13 factors compared between the two stocks.
About Columbia Laboratories
Juniper Pharmaceuticals, Inc., a women's health therapeutic company, focuses on developing therapeutics that address unmet medical needs in women's health. The company develops its products using its drug delivery technologies, including bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product; and a novel intra-vaginal ring (IVR) technology. It markets CRINONE, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. The company is also developing COL-1077, a lidocaine bioadhesive gel, which is in Phase 2b clinical trial for use as an acute use anesthetic for pain from minimally invasive gynecological procedures. Its products in preclinical development include JNP-0101, an oxybutynin IVR to treat overactive bladder in women; JNP-0201, a product candidate with natural progesterone and natural estradiol for used in hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone IVR used for the prevention of preterm birth. In addition, Juniper Pharmaceuticals, Inc. provides pharmaceutical development, clinical trial manufacturing, analytical, and consulting services. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is based in Boston, Massachusetts.
About Theravance Biopharma
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
Receive News & Ratings for Columbia Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Columbia Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.